KRRO
HEALTHCAREKorro Bio Inc
$13.34+0.75 (+5.96%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving KRRO Today?
No stock-specific AI insight has been generated for KRRO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.20$55.89
$13.34
Fundamentals
Market Cap$192M
P/E Ratio—
EPS$-12.48
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume92K
Avg Volume (10D)—
Shares Outstanding14.4M
KRRO News
20 articles- Korro Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 7, 2026
- Korro to Participate in Upcoming Investor ConferencesYahoo Finance·May 5, 2026
- What Makes Korro Bio, Inc. (KRRO) a New Buy StockYahoo Finance·Apr 28, 2026
- Korro Announces Oral and Poster Presentations at Upcoming Scientific ConferencesYahoo Finance·Apr 16, 2026
- Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 10, 2026
- Top 5 Insider Buys From Q1: Buy, Sell, or Hold in Q2?Insidertrades·Apr 6, 2026
- Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 12, 2026
- Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 12, 2026
- United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?Yahoo Finance·Mar 10, 2026
- Korro Announces Oversubscribed $85 Million Private PlacementYahoo Finance·Mar 9, 2026
- Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss EstimatesYahoo Finance·Feb 26, 2026
- Korro to Present at the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 25, 2026
- We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth CarefullyYahoo Finance·Feb 13, 2026
- H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO)Yahoo Finance·Feb 2, 2026
- Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?Yahoo Finance·Jan 30, 2026
- Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HEMarketbeat·Jan 30, 2026
- First Solar downgraded, Fortinet upgraded: Wall Street's top analyst callsYahoo Finance·Jan 29, 2026
- Korro to Host Virtual Analyst Day on January 27, 2026Yahoo Finance·Jan 20, 2026
- Korro to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 8, 2026
- Korro Bio (KRRO): Assessing Valuation After Clinical Setbacks, Layoffs, and Strategic PivotYahoo Finance·Nov 15, 2025
All 20 articles loaded
Price Data
Open$12.72
Previous Close$12.59
Day High$13.51
Day Low$12.34
52 Week High$55.89
52 Week Low$5.20
52-Week Range
$5.20$55.89
$13.34
Fundamentals
Market Cap$192M
P/E Ratio—
EPS$-12.48
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume92K
Avg Volume (10D)—
Shares Outstanding14.4M
About Korro Bio Inc
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—